Rising hospital risks
Bloodstream infections caused by treatment-resistant Klebsiella pneumoniae increased 72% between 2019 and 2025, according to the European Centre for Disease Prevention and Control. This surge misses the 2030 target to cut infection rates by 5%. These infections cause severe illness and death, with mortality rates typically between 40% and 70%. Christian Giske, who leads this work at ECDC, told a press briefing that these findings were "the biggest concern" among all data collected on superbugs in Europe over the past year. Because the bacterium spreads between patients, hospitals must strengthen hand hygiene, ensure correct use of personal protective equipment, and improve environmental cleaning. While infection control measures helped reduce MRSA rates by 19% between 2019 and 2025, Christian Giske noted that Klebsiella is harder to tackle because the bacterium may have more powerful reservoirs in the body. Klebsiella strains are becoming resistant to nearly all antibiotics, including new ones, making this a "major public health threat," Giske said.
Targets for resistance
The EU struggles to meet its 2030 goals for antimicrobial resistance, which kills an estimated 35,000 people in the EU, Iceland, and Norway every year. E. coli drug-resistant infections rose 16.4% between 2019 and 2025, failing the 10% reduction target. In 2025, bloodstream infections caused by MRSA, also known as drug-resistant Staphylococcus aureus, were 19% lower than in 2019, surpassing the 15% reduction target.
| Infection Type | 2019-2025 Change | 2030 Target |
|---|---|---|
| Klebsiella pneumoniae | 72% increase | 5% reduction |
| E. coli | 16.4% increase | 10% reduction |
| MRSA | 19% reduction | 15% reduction |
The proportion of antibiotics used in Europe that are the correct drugs reached 62.5% in 2025, which is nearing the 65% goal. Antibiotic consumption in the EU dropped by 5% between 2019 and 2025, failing to meet the 20% target by 2030. ECDC Director Pamela Rendi-Wagner said in a statement that the EU is "still behind with several of the EU’s 2030 targets to counter antimicrobial resistance." Legislation scheduled for signing in December includes measures to boost the discovery and development of new antibiotics through a market monopoly perk for industry and steady payment models for countries to buy them. Genomic surveillance helps authorities assess how resistant bacteria spread, which allows them to guide treatment decisions and identify where new antibiotics are most urgently needed. This innovation enables authorities to act sooner to stop transmission.
